Kymera Therapeutics, Inc. (NASDAQ: KYMR) had its price target lowered by analysts at Wells Fargo & Company from $62.00 to $35.00.
Kymera Therapeutics, Inc. (KYMR)
Company Research
Source: MarketBeat
Impact Snapshot
Event Time:
KYMR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KYMR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KYMR alerts
High impacting Kymera Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
KYMR
News
- Kymera Therapeutics Doses First Patients in Phase 1 Oncology Trials of STAT3 and IRAKIMiD Degraders KT-333 and KT-413PR Newswire
- Kymera Therapeutics Receives FDA Orphan Drug Designation For KT-333, A First-in-Class, Investigational STAT3 Degrader For The Treatment Of Peripheral T-Cell Lymphoma [TheStreet.com]TheStreet.com
- Kymera Therapeutics Receives FDA Orphan Drug Designation for KT-333, a First-in-Class, Investigational STAT3 Degrader for the Treatment of Peripheral T-Cell LymphomaGlobeNewswire
- Kymera Therapeutics To Present Pre-clinical Data At The EULAR 2022 Congress Showing STAT3 Degradation Blocked Th17 Development And Prevented Rheumatoid Arthritis [TheStreet.com]TheStreet.com
- Kymera Therapeutics to Present Pre-clinical Data at the EULAR 2022 Congress Showing STAT3 Degradation Blocked Th17 Development and Prevented Rheumatoid ArthritisGlobeNewswire
KYMR
Earnings
- 5/3/22 - Miss
KYMR
Sec Filings
- 7/1/22 - Form 4
- 6/17/22 - Form 4
- 6/16/22 - Form 4
- KYMR's page on the SEC website